Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/69806
HOW TO REDUCE HOUSEHOLD COSTS FOR PEOPLE WITH TUBERCULOSIS: A LONGITUDINAL COSTING SURVEY IN NEPAL
Author
Gurung, Suman Chandra
Rai, Bhola
Dixit, Kritika
Worrall, Eve
Paudel, Puskar Raj
Dhital, Raghu
Sah, Manoj Kumar
Pandit, Ram Narayan
Aryal, Tara Prasad
Majhi, Govinda
Wingfield, Tom
Squire, Bertie
Lönnroth, Knut
Levy, Jens W
Viney, Kerri
van Rest, Job
Ramsay, Andrew
Santos da Costa, Rafaely Marcia
Basnyat, Buddha
Thapa, Anil
Mishra, Gokul
Moreira Pescarini, Julia
Caws, Maxine
Teixeira de Siqueira-Filha, Noemia
Rai, Bhola
Dixit, Kritika
Worrall, Eve
Paudel, Puskar Raj
Dhital, Raghu
Sah, Manoj Kumar
Pandit, Ram Narayan
Aryal, Tara Prasad
Majhi, Govinda
Wingfield, Tom
Squire, Bertie
Lönnroth, Knut
Levy, Jens W
Viney, Kerri
van Rest, Job
Ramsay, Andrew
Santos da Costa, Rafaely Marcia
Basnyat, Buddha
Thapa, Anil
Mishra, Gokul
Moreira Pescarini, Julia
Caws, Maxine
Teixeira de Siqueira-Filha, Noemia
Affilliation
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK / Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden / Australian National University. Research School of Population Health. College of Health & Medicine. Canberra, ACT 2600, Australia.
KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
University of St Andrews. College Gate St Andrews. St Andrews, KY16 9AJ, UK.
Oswaldo Cruz Foundation. Centro de Pesquisa Aggeu Magalhaes. Recife, PE, Brazil.
Oxford University Clinical Research Unit. Kathmandu, Nepal.
National Tuberculosis Control Centre. Thimi, Bhaktapur, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Oswaldo Cruz Foundation. Gonçalo Muniz Institute. Center for Data and Knowledge Integration for Health. Salvador, BA, Brazil.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK / University of York. Department of Helarh Sciences, Heslington. York, UK.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK / Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden.
KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
Karolinska Institutet. Department of Global Public Health. Stockholm, Sweden / Australian National University. Research School of Population Health. College of Health & Medicine. Canberra, ACT 2600, Australia.
KNCV Tuberculosis Foundation. Maanweg 174, 2516 AB. Den Haag, the The Netherlands.
University of St Andrews. College Gate St Andrews. St Andrews, KY16 9AJ, UK.
Oswaldo Cruz Foundation. Centro de Pesquisa Aggeu Magalhaes. Recife, PE, Brazil.
Oxford University Clinical Research Unit. Kathmandu, Nepal.
National Tuberculosis Control Centre. Thimi, Bhaktapur, Nepal.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Oswaldo Cruz Foundation. Gonçalo Muniz Institute. Center for Data and Knowledge Integration for Health. Salvador, BA, Brazil.
Birat Nepal Medical Trust. Lazimpat, Ward No. 2, Kathmandu, Nepal / Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK.
Department of Clinical Sciences. Liverpool School of Tropical Medicine. Pembroke Place, Liverpool L3 5QA, UK / University of York. Department of Helarh Sciences, Heslington. York, UK.
Abstract
The aim of this study was to compare costs and socio-economic impact of tuberculosis (TB) for patients diagnosed through active (ACF) and passive case finding (PCF) in Nepal. A longitudinal costing survey was conducted in four districts of Nepal from April 2018 to October 2019. Costs were collected using the WHO TB Patient Costs Survey at three time points: intensive phase of treatment, continuation phase of treatment and at treatment completion. Direct and indirect costs and socio-economic impact (poverty headcount, employment status and coping strategies) were evaluated throughout the treatment. Prevalence of catastrophic costs was estimated using the WHO threshold. Logistic regression and generalized estimating equation were used to evaluate risk of incurring high costs, catastrophic costs and socio-economic impact of TB over time. A total of 111 ACF and 110 PCF patients were included. ACF patients were more likely to have no education (75% vs 57%, P = 0.006) and informal employment (42% vs 24%, P = 0.005) Compared with the PCF group, ACF patients incurred lower costs during the pretreatment period (mean total cost: US$55 vs US$87, P < 0.001) and during the pretreatment plus treatment periods (mean total direct costs: US$72 vs US$101, P < 0.001). Socio-economic impact was severe for both groups throughout the whole treatment, with 32% of households incurring catastrophic costs. Catastrophic costs were associated with 'no education' status [odds ratio = 2.53(95% confidence interval = 1.16-5.50)]. There is a severe and sustained socio-economic impact of TB on affected households in Nepal. The community-based ACF approach mitigated costs and reached the most vulnerable patients. Alongside ACF, social protection policies must be extended to achieve the zero catastrophic costs milestone of the End TB strategy.
Share